IGC Pharma, Inc. (NYSEAMERICAN:IGC – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.00 and traded as high as $0.33. IGC Pharma shares last traded at $0.32, with a volume of 132,947 shares changing hands.
IGC Pharma Trading Down 2.4 %
The company has a debt-to-equity ratio of 0.01, a current ratio of 2.38 and a quick ratio of 1.14. The stock has a market cap of $17.19 million, a PE ratio of -1.52 and a beta of 1.73.
IGC Pharma (NYSEAMERICAN:IGC – Get Free Report) last issued its earnings results on Thursday, August 10th. The construction company reported ($0.04) earnings per share (EPS) for the quarter. The firm had revenue of $0.56 million during the quarter. IGC Pharma had a negative net margin of 860.24% and a negative return on equity of 64.87%.
Institutional Trading of IGC Pharma
IGC Pharma Company Profile
IGC Pharma, Inc, a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development.
- Five stocks we like better than IGC Pharma
- Options Trading – Understanding Strike Price
- Investing in large cap stocks: Diving into big caps
- What is Forex and How Does it Work?
- Why you can make Vertex Pharmaceuticals a buy on any pullback
- How to Invest in Biotech Stocks
- Occidental Petroleum: Another bounce from the buy zone
Receive News & Ratings for IGC Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGC Pharma and related companies with MarketBeat.com's FREE daily email newsletter.